Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Metis Global Partners LLC

Metis Global Partners LLC lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,209 shares of the medical research company’s stock after buying an additional 3,340 shares during the period. Metis Global Partners LLC’s holdings in Edwards Lifesciences were worth $2,719,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences during the first quarter worth about $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $29,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences in the 2nd quarter valued at approximately $39,000. Peoples Bank KS acquired a new position in Edwards Lifesciences during the third quarter worth $40,000. Finally, Versant Capital Management Inc boosted its position in Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 0.6 %

Shares of EW opened at $66.15 on Friday. The stock’s fifty day simple moving average is $67.42 and its 200 day simple moving average is $76.44. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $39.02 billion, a P/E ratio of 9.55, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.59 EPS. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on EW. Barclays cut their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $75.67.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,250 shares of company stock valued at $2,744,438 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.